Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 497

1.

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.

Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet EM, Hauptrock B, Dreger P, Luft T, Bethge W, Vogel W, Ciceri F, Peccatori J, Stölzel F, Schetelig J, Junghanß C, Grosse-Thie C, Michallet M, Labussiere-Wallet H, Schaefer-Eckart K, Dressler S, Grigoleit GU, Mielke S, Scheid C, Holtick U, Patriarca F, Medeot M, Rambaldi A, Micò MC, Niederwieser D, Franke GN, Hilgendorf I, Winkelmann NR, Russo D, Socié G, Peffault de Latour R, Holler E, Wolff D, Glass B, Casper J, Wulf G, Menzel H, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, Grass S, Iori AP, Finke J, Benedetti F, Pichlmeier U, Hemmelmann C, Tribanek M, Klein A, Mylius HA, Baumgart J, Dzierzak-Mietla M, Markiewicz M.

Lancet Haematol. 2019 Oct 9. pii: S2352-3026(19)30157-7. doi: 10.1016/S2352-3026(19)30157-7. [Epub ahead of print]

PMID:
31606445
2.

Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.

Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, Peest D, Kaufmann M, Bunjes D, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Bassermann F, Hess G, Hertenstein B, Freund M, Kropff M, Schmidt CA, Wolf HH, Jung W, Frickhofen N, Mielke S, Bargou RC, Maschmeyer G, Svaldi M, Langer CH, Gramatzki M, Hebart H, Kanz L, Einsele H; Deutsche Studiengruppe Multiples Myelom.

Leukemia. 2019 Aug 28. doi: 10.1038/s41375-019-0537-2. [Epub ahead of print]

PMID:
31462732
3.

Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.

Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, Klymyshyn D, Tourtellotte WG, Israel LL, Braubach O, Ljubimov VA, Mashouf LA, Ramesh A, Grodzinski ZB, Penichet ML, Black KL, Holler E, Sun T, Ding H, Ljubimov AV, Ljubimova JY.

Nat Commun. 2019 Aug 28;10(1):3850. doi: 10.1038/s41467-019-11719-3.

4.

Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease-single center experience.

Klobuch S, Weber D, Holler B, Edinger M, Herr W, Holler E, Wolff D.

Ann Hematol. 2019 Oct;98(10):2399-2405. doi: 10.1007/s00277-019-03768-x. Epub 2019 Aug 3.

PMID:
31375860
5.

Haploidentical CD3 or α/β T-cell depleted HSCT in advanced stage sickle cell disease.

Foell J, Schulte JH, Pfirstinger B, Troeger A, Wolff D, Edinger M, Hofmann P, Aslanidis C, Lang P, Holler E, Eggert A, Corbacioglu S.

Bone Marrow Transplant. 2019 May 14. doi: 10.1038/s41409-019-0550-0. [Epub ahead of print]

PMID:
31089288
6.

Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients.

Lamby P, Wolff D, Mielke S, Grigoleit GU, Ljungman P, Hilgendorf I, Holler E, Holler B, Weber D, Herr W, Schiltz D, Klein S, Graf S, Bjornhagen-Safwenberg V, Dolderer J, Prantl L.

Ann Hematol. 2019 Aug;98(8):1867-1875. doi: 10.1007/s00277-019-03687-x. Epub 2019 Apr 16.

PMID:
30993415
7.

Polymalic acid chlorotoxin nanoconjugate for near-infrared fluorescence guided resection of glioblastoma multiforme.

Patil R, Galstyan A, Sun T, Shatalova ES, Butte P, Mamelak AN, Carico C, Kittle DS, Grodzinski ZB, Chiechi A, Ding H, Black KL, Ljubimova JY, Holler E.

Biomaterials. 2019 Jun;206:146-159. doi: 10.1016/j.biomaterials.2019.03.029. Epub 2019 Mar 23.

8.

Quantification of Fecal Short Chain Fatty Acids by Liquid Chromatography Tandem Mass Spectrometry-Investigation of Pre-Analytic Stability.

Liebisch G, Ecker J, Roth S, Schweizer S, Öttl V, Schött HF, Yoon H, Haller D, Holler E, Burkhardt R, Matysik S.

Biomolecules. 2019 Mar 28;9(4). pii: E121. doi: 10.3390/biom9040121.

9.

Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.

Wolff D, Hilgendorf I, Wagner-Drouet E, Jedlickova Z, Ayuk F, Zeiser R, Schäfer-Eckart K, Gerbitz A, Stadler M, Klein S, Middeke JM, Lawitschka A, Winkler J, Halter J, Holler E, Kobbe G, Stelljes M, Ditschkowski M, Greinix H.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1450-1455. doi: 10.1016/j.bbmt.2019.03.003. Epub 2019 Mar 13.

PMID:
30876928
10.

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.

Robin M, de Wreede LC, Wolschke C, Schetelig J, Eikema DJ, Van Lint MT, Knelange NS, Beelen D, Brecht A, Niederwieser D, Vitek A, Bethge W, Arnold R, Finke J, Volin L, Yakoub-Agha I, Nagler A, Poiré X, Einsele H, Chevallier P, Holler E, Ljungman P, Robinson S, Radujkovic A, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Sep;104(9):1782-1788. doi: 10.3324/haematol.2018.205211. Epub 2019 Feb 7.

11.

Blockade of a Laminin-411-Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk.

Sun T, Patil R, Galstyan A, Klymyshyn D, Ding H, Chesnokova A, Cavenee WK, Furnari FB, Ljubimov VA, Shatalova ES, Wagner S, Li D, Mamelak AN, Bannykh SI, Patil CG, Rudnick JD, Hu J, Grodzinski ZB, Rekechenetskiy A, Falahatian V, Lyubimov AV, Chen YL, Leoh LS, Daniels-Wells TR, Penichet ML, Holler E, Ljubimov AV, Black KL, Ljubimova JY.

Cancer Res. 2019 Mar 15;79(6):1239-1251. doi: 10.1158/0008-5472.CAN-18-2725. Epub 2019 Jan 18.

PMID:
30659021
12.

A Combination of Tri-Leucine and Angiopep-2 Drives a Polyanionic Polymalic Acid Nanodrug Platform Across the Blood-Brain Barrier.

Israel LL, Braubach O, Galstyan A, Chiechi A, Shatalova ES, Grodzinski Z, Ding H, Black KL, Ljubimova JY, Holler E.

ACS Nano. 2019 Feb 26;13(2):1253-1271. doi: 10.1021/acsnano.8b06437. Epub 2019 Jan 16.

PMID:
30633492
13.

Non-invasive diagnosis of acute intestinal graft-versus-host disease by a new scoring system using ultrasound morphology, compound elastography, and contrast-enhanced ultrasound.

Weber D, Weber M, Hippe K, Ghimire S, Wolff D, Hahn J, Evert M, Herr W, Holler E, Jung EM.

Bone Marrow Transplant. 2019 Jul;54(7):1038-1048. doi: 10.1038/s41409-018-0381-4. Epub 2018 Nov 6.

PMID:
30401964
14.

Persistent polyomavirus-associated nephropathy in a patient with GvHD and treatment with the JAK1/2 inhibitor ruxolitinib.

Fante MA, Holler E, Schmidt B, Wolff D, Ehrl Y, Plentz A.

Bone Marrow Transplant. 2019 May;54(5):762-764. doi: 10.1038/s41409-018-0370-7. Epub 2018 Oct 22. No abstract available.

PMID:
30349038
15.

Editorial: Cellular Therapies: Past, Present and Future.

Dressel R, Greinix HT, Holler E, Dickinson AM.

Front Immunol. 2018 Aug 30;9:1966. doi: 10.3389/fimmu.2018.01966. eCollection 2018. No abstract available.

16.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL.

JCI Insight. 2018 Aug 23;3(16). pii: 124015. doi: 10.1172/jci.insight.124015. eCollection 2018 Aug 23. No abstract available.

17.

Detrimental Effect of Broad-spectrum Antibiotics on Intestinal Microbiome Diversity in Patients After Allogeneic Stem Cell Transplantation: Lack of Commensal Sparing Antibiotics.

Weber D, Hiergeist A, Weber M, Dettmer K, Wolff D, Hahn J, Herr W, Gessner A, Holler E.

Clin Infect Dis. 2019 Apr 8;68(8):1303-1310. doi: 10.1093/cid/ciy711.

PMID:
30124813
18.

[Tauopathies : From molecule to therapy].

Kovacs GG, Respondek G, van Eimeren T, Höller E, Levin J, Müller U, Schwarz S, Rösler TW, Schweyer K, Höglinger GU.

Nervenarzt. 2018 Oct;89(10):1083-1094. doi: 10.1007/s00115-018-0584-3. German.

PMID:
30120488
19.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, Lee SJ, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Cutler CS, Arai S, Lazaryan A, Newell LF, Jagasia MH, Pusic I, Wood WA, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera YA, Ferrara JLM, Pidala J, Howard A, Wu J, Bolaños-Meade J, Ho V, Alousi A, Blazar BR, Weisdorf DJ, MacMillan ML.

Blood Adv. 2018 Aug 14;2(15):1882-1888. doi: 10.1182/bloodadvances.2018017343.

20.

The influence of glucocorticoid receptor single nucleotide polymorphisms on outcome after haematopoietic stem cell transplantation.

Norden J, Pearce KF, Irving JAE, Collin MP, Wang XN, Wolff D, Kolb HJ, Socie G, Kuzmina Z, Greinix H, Holler E, Rocha V, Gluckman E, Hromadnikova I, Dickinson AM.

Int J Immunogenet. 2018 Jul 25. doi: 10.1111/iji.12380. [Epub ahead of print]

PMID:
30043490
21.

Targeting Inflammatory T Helper Cells via Retinoic Acid-Related Orphan Receptor Gamma t Is Ineffective to Prevent Allo-Response-Driven Colitis.

Buchele V, Abendroth B, Büttner-Herold M, Vogler T, Rothamer J, Ghimire S, Ullrich E, Holler E, Neurath MF, Hildner K.

Front Immunol. 2018 May 25;9:1138. doi: 10.3389/fimmu.2018.01138. eCollection 2018.

22.

EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment.

Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, Shaw BE, Flowers ME, Ruutu T, Greinix H, Holler E, Basak G, Duarte RF, Pavletic SZ; EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (National Institutes of Health)−CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force”.

Bone Marrow Transplant. 2018 Nov;53(11):1401-1415. doi: 10.1038/s41409-018-0204-7. Epub 2018 Jun 5.

PMID:
29872128
23.

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.

McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, Van Lint MT, Finke J, Vitek A, Carlson K, Griskevicius L, Holler E, Itälä-Remes M, Schaap M, Socié G, Bay JO, Beguin Y, Bruno B, Cornelissen JJ, Gedde-Dahl T, Ljungman P, Rubio MT, Yakoub-Agha I, Klyuchnikov E, Olavarria E, Chalandon Y, Kröger N.

Br J Haematol. 2018 Aug;182(3):418-422. doi: 10.1111/bjh.15407. Epub 2018 May 29.

24.

Coarse particulate matter (PM2.5-10) in Los Angeles Basin air induces expression of inflammation and cancer biomarkers in rat brains.

Ljubimova JY, Braubach O, Patil R, Chiechi A, Tang J, Galstyan A, Shatalova ES, Kleinman MT, Black KL, Holler E.

Sci Rep. 2018 Apr 9;8(1):5708. doi: 10.1038/s41598-018-23885-3.

25.

Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma.

Heinzelmann F, Bethge W, Beelen DW, Stelljes M, Dreger P, Engelhard M, Finke J, Kröger N, Holler E, Bornhäuser M, Müller A, Haubitz I, Ottinger H.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1173-1183. doi: 10.1007/s00432-018-2633-5. Epub 2018 Apr 5.

PMID:
29623467
26.

Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.

DeFilipp Z, Peled JU, Li S, Mahabamunuge J, Dagher Z, Slingerland AE, Del Rio C, Valles B, Kempner ME, Smith M, Brown J, Dey BR, El-Jawahri A, McAfee SL, Spitzer TR, Ballen KK, Sung AD, Dalton TE, Messina JA, Dettmer K, Liebisch G, Oefner P, Taur Y, Pamer EG, Holler E, Mansour MK, van den Brink MRM, Hohmann E, Jenq RR, Chen YB.

Blood Adv. 2018 Apr 10;2(7):745-753. doi: 10.1182/bloodadvances.2018017731.

27.

MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.

Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera YA, Hogan WJ, Wölfl M, Qayed M, Hexner EO, Wudhikarn K, Ordemann R, Young R, Shah J, Hartwell MJ, Chaudhry MS, Aziz M, Etra A, Yanik GA, Kröger N, Weber D, Chen YB, Nakamura R, Rösler W, Kitko CL, Harris AC, Pulsipher M, Reshef R, Kowalyk S, Morales G, Torres I, Özbek U, Ferrara JLM, Levine JE.

Blood. 2018 Jun 21;131(25):2846-2855. doi: 10.1182/blood-2018-01-822957. Epub 2018 Mar 15.

28.

The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future.

Andermann TM, Peled JU, Ho C, Reddy P, Riches M, Storb R, Teshima T, van den Brink MRM, Alousi A, Balderman S, Chiusolo P, Clark WB, Holler E, Howard A, Kean LS, Koh AY, McCarthy PL, McCarty JM, Mohty M, Nakamura R, Rezvani K, Segal BH, Shaw BE, Shpall EJ, Sung AD, Weber D, Whangbo J, Wingard JR, Wood WA, Perales MA, Jenq RR, Bhatt AS; Blood and Marrow Transplant Clinical Trials Network.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1322-1340. doi: 10.1016/j.bbmt.2018.02.009. Epub 2018 Feb 19. Review. No abstract available.

29.

BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease.

Ullrich E, Abendroth B, Rothamer J, Huber C, Büttner-Herold M, Buchele V, Vogler T, Longerich T, Zundler S, Völkl S, Beilhack A, Rose-John S, Wirtz S, Weber GF, Ghimire S, Kreutz M, Holler E, Mackensen A, Neurath MF, Hildner K.

J Clin Invest. 2018 Mar 1;128(3):916-930. doi: 10.1172/JCI89242. Epub 2018 Jan 29.

30.

Biomarkers in chronic graft-versus-host disease: quo vadis?

Wolff D, Greinix H, Lee SJ, Gooley T, Paczesny S, Pavletic S, Hakim F, Malard F, Jagasia M, Lawitschka A, Hansen JA, Pulanic D, Holler E, Dickinson A, Weissinger E, Edinger M, Sarantopoulos S, Schultz KR.

Bone Marrow Transplant. 2018 Jul;53(7):832-837. doi: 10.1038/s41409-018-0092-x. Epub 2018 Jan 24.

31.

Indoxyl 3-sulfate inhibits maturation and activation of human monocyte-derived dendritic cells.

Ghimire S, Matos C, Caioni M, Weber D, Peter K, Holler E, Kreutz M, Renner K.

Immunobiology. 2018 Feb;223(2):239-245. doi: 10.1016/j.imbio.2017.10.014. Epub 2017 Oct 6.

PMID:
29100619
32.

Polymalic Acid Tritryptophan Copolymer Interacts with Lipid Membrane Resulting in Membrane Solubilization.

Ding H, Fox I, Patil R, Galstyan A, Black KL, Ljubimova JY, Holler E.

J Nanomater. 2017;2017. pii: 4238697. doi: 10.1155/2017/4238697. Epub 2017 May 21.

33.

The association between acute graft-versus-host disease and antimicrobial peptide expression in the gastrointestinal tract after allogeneic stem cell transplantation.

Weber D, Frauenschläger K, Ghimire S, Peter K, Panzer I, Hiergeist A, Weber M, Kutny D, Wolff D, Grube M, Huber E, Oefner P, Gessner A, Hehlgans T, Herr W, Holler E.

PLoS One. 2017 Sep 21;12(9):e0185265. doi: 10.1371/journal.pone.0185265. eCollection 2017.

34.

Acute Renal Graft-Versus-Host Disease in a Murine Model of Allogeneic Bone Marrow Transplantation.

Schmid PM, Bouazzaoui A, Schmid K, Birner C, Schach C, Maier LS, Holler E, Endemann DH.

Cell Transplant. 2017 Aug;26(8):1428-1440. doi: 10.1177/0963689717720295.

35.

Acute Ocular Graft-versus-Host Disease.

Braun R, Holler E.

N Engl J Med. 2017 Aug 17;377(7):676. doi: 10.1056/NEJMicm1701185. No abstract available.

36.

Potential Role of the PD-1/PD-L1 Axis in the Immune Regulation of Chronic GVHD.

Klobuch S, Weber D, Holler B, Herr W, Holler E, Wolff D.

Oncol Res Treat. 2017;40(7-8):447-450. doi: 10.1159/000471768. Epub 2017 Jun 30.

37.

Endothelial damage is aggravated in acute GvHD and could predict its development.

Mir E, Palomo M, Rovira M, Pereira A, Escolar G, Penack O, Holler E, Carreras E, Diaz-Ricart M.

Bone Marrow Transplant. 2017 Sep;52(9):1317-1325. doi: 10.1038/bmt.2017.121. Epub 2017 Jun 26.

PMID:
28650450
38.

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.

Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Schäfer-Eckart K, Zander AR, Bunjes D, Mielke S, Bethge WA, Milpied N, Kalhs P, Blau IW, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A.

J Hematol Oncol. 2017 Jun 24;10(1):130. doi: 10.1186/s13045-017-0498-8.

39.

Complementary and Alternative Medicine: A Clinical Study in 1,016 Hematology/Oncology Patients.

Hierl M, Pfirstinger J, Andreesen R, Holler E, Mayer S, Wolff D, Vogelhuber M.

Oncology. 2017;93(3):157-163. doi: 10.1159/000464248. Epub 2017 Jun 23.

PMID:
28641281
40.

Covalent nano delivery systems for selective imaging and treatment of brain tumors.

Ljubimova JY, Sun T, Mashouf L, Ljubimov AV, Israel LL, Ljubimov VA, Falahatian V, Holler E.

Adv Drug Deliv Rev. 2017 Apr;113:177-200. doi: 10.1016/j.addr.2017.06.002. Epub 2017 Jun 10. Review.

41.

Haploidentical stem cell transplantation with CD3+-/CD19+- depleted peripheral stem cells for patients with advanced stage sickle cell disease and no alternative donor: results of a pilot study.

Foell J, Pfirstinger B, Rehe K, Wolff D, Holler E, Corbacioglu S.

Bone Marrow Transplant. 2017 Jun;52(6):938-940. doi: 10.1038/bmt.2017.49. Epub 2017 Apr 24. No abstract available.

PMID:
28436975
42.

Pathophysiology of GvHD and Other HSCT-Related Major Complications.

Ghimire S, Weber D, Mavin E, Wang XN, Dickinson AM, Holler E.

Front Immunol. 2017 Mar 20;8:79. doi: 10.3389/fimmu.2017.00079. eCollection 2017. Review.

43.

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Onida F, de Wreede LC, van Biezen A, Eikema DJ, Byrne JL, Iori AP, Schots R, Jungova A, Schetelig J, Finke J, Veelken H, Johansson JE, Craddock C, Stelljes M, Theobald M, Holler E, Schanz U, Schaap N, Bittenbring J, Olavarria E, Chalandon Y, Kröger N.

Br J Haematol. 2017 Jun;177(5):759-765. doi: 10.1111/bjh.14619. Epub 2017 Mar 28.

PMID:
28369779
44.

[Bilateral ciliary body oedema under treatment with ciclosporine].

Braun R, Holler E, Wolff D, Helbig H, Blecha C, Dietrich-Ntoukas T.

Ophthalmologe. 2018 Jan;115(1):55-58. doi: 10.1007/s00347-017-0475-1. German.

PMID:
28251308
45.

Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation.

Weber D, Jenq RR, Peled JU, Taur Y, Hiergeist A, Koestler J, Dettmer K, Weber M, Wolff D, Hahn J, Pamer EG, Herr W, Gessner A, Oefner PJ, van den Brink MRM, Holler E.

Biol Blood Marrow Transplant. 2017 May;23(5):845-852. doi: 10.1016/j.bbmt.2017.02.006. Epub 2017 Feb 14.

46.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL.

JCI Insight. 2017 Feb 9;2(3):e89798. doi: 10.1172/jci.insight.89798. Erratum in: JCI Insight. 2018 Aug 23;3(16):.

47.

Fit for cure? Microbiota and GVHD.

Holler E, Weber D.

Blood. 2016 Oct 20;128(16):2004-2005. doi: 10.1182/blood-2016-08-732156. No abstract available.

PMID:
28157678
48.

B-Cell-Based and Soluble Biomarkers in Body Liquids for Predicting Acute/Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Juric MK, Shevtsov M, Mozes P, Ogonek J, Crossland RE, Dickinson AM, Greinix HT, Holler E, Weissinger EM, Multhoff G.

Front Immunol. 2017 Jan 16;7:660. doi: 10.3389/fimmu.2016.00660. eCollection 2016. Review.

49.

Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation.

Ullrich E, Salzmann-Manrique E, Bakhtiar S, Bremm M, Gerstner S, Herrmann E, Bader P, Hoffmann P, Holler E, Edinger M, Wolff D.

Front Immunol. 2016 Dec 22;7:595. doi: 10.3389/fimmu.2016.00595. eCollection 2016.

50.

Reduction of aGVHD using chicken antibodies directed against intestinal pathogens in a murine model.

Bouazzaoui A, Huber E, Dan A, Al-Allaf FA, Pfirstinger J, Sprotte G, Köstler J, Hiergeist A, Gessner A, Herr W, Holler E.

Blood. 2017 Feb 23;129(8):1052-1055. doi: 10.1182/blood-2016-06-722538. Epub 2016 Dec 23. No abstract available.

Supplemental Content

Loading ...
Support Center